Press Releases

CRANBURY, N.J., Sept. 14, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year end 2016 operating results on Tuesday, September 20, 2016  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September

CRANBURY, N.J., Aug. 8, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Carl Spana, the Company’s President & Chief Executive Officer, will present at the 36th Annual Canaccord Genuity Growth Conference

CRANBURY, N.J., Aug. 4, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient visits in the Company’s reconnect studies, consisting of two pivotal Phase 3 clinical trials of bremelanotide for the treatment of female hypoactive sexual desire disorder (HSDD), have been completed. “We are very excited with the completion of

CRANBURY, N.J., Aug. 4, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that today it closed on a previously disclosed underwritten offering of units with gross proceeds of $9,225,000.  Canaccord Genuity Inc. acted

CRANBURY, N.J., Aug. 1, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has priced an underwritten offering of units with anticipated gross proceeds of $9.25 million.  Each unit will consist of a share of common stock and a Series H warrant to purchase 0.75 of a share of common stock.  Investors

CRANBURY, N.J., June 6, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application Serial

CRANBURY, N.J., May 26, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial

CRANBURY, N.J., May 17, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2016.  Quarter Ended March 31, 2016 and Recent Highlights Bremelanotide development for

CRANBURY, N.J., May 12, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2016 operating results on Tuesday, May 17, 2016  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 17,

CRANBURY, N.J., Feb. 26, 2016 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that data on a bremelanotide and alcohol use interaction Phase 1 study were presented today in a Research Podium Session